

REMARKS

I. AMENDMENTS TO THE SPECIFICATION

The specification has been amended to update the domestic priority information, to replace the Sequence Listing at pages 95-98 with a new Sequence Listing, to conform the description of the figures to comport with the formal versions of the figures, and to conform the sequence identification number descriptions (SEQ ID NOs) with the Sequence Listing, and to correct an obvious typographical error.

The paragraph on page 1, lines 8-13, was amended to update domestic priority information in the application. The amended domestic priority information includes the complete chain of priority and the patent numbers of the issued U.S. patents. This paper is accompanied by a Request for Corrected Filing Receipt.

The Sequence Listing at pages 95-98 has been replaced with a new Sequence Listing. The Sequence Listing, as originally filed, incorrectly presented only two of the three sequences disclosed in the application. In order to correct this error, Applicant submits a new Sequence Listing which contains the third sequence (SEQ ID NO: 3). Since the sequence identified by SEQ ID NO:3 is the same sequence as was originally disclosed in Figure 13 of the instant application, the addition of SEQ ID NO: 3 does not introduced new matter.

The paragraphs on page 53, lines 5-12; lines 14-19; and lines 20-26 have been amended to conform the description of the figures to comport to the formal versions of the figures.

The paragraphs on page 92, lines 2-15; page 93, lines 2-15 and lines 23-29 have been amended to conform the sequence identification number descriptions (SEQ ID NOs) with the Sequence Listing.

The paragraph on page 10, lines 20-21; and page 11, lines 1-4 has been amended to correct an obvious minor typographical error. The chemical structure at page 11, lines 1-3 includes R₁₁ though R₁₆. The paragraph has been amended to replace R₁₇ with R₁₆ to correct the error in the description of the chemical structure.

The above-mentioned amendments do not introduce new matter into the instant application. Entry of these amendments into the application is therefore respectfully requested.

II. AMENDMENT TO THE DRAWINGS

Figure 4 (drawing sheet 5 and sheet 6) has been amended to correct errors in the drawings. Replacement sheets for drawing sheet 5 and sheet 6 are provided in Attachment B labeled "Replacement Sheets". Marked-up copies showing the changes to drawing sheet 5 and sheet 6 are provided in Attachment C labeled "Annotated Marked-up Drawings". Bases for the amendment is found in the 16 sheets of drawings as filed with the application and the specification at page 47, lines 15-25.

The above-mentioned amendment does not introduce new matter into the instant application. Entry of the amendment into the application is therefore respectfully requested.

III. RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR NUCLEOTIDE SEQUENCES

This application is a continuation of application Serial No. 10/014,743 (the "parent '743 application"). A computer readable form (CFR) of a Sequence Listing that is identical in content to the paper copy of the replacement Sequence Listing being submitted concurrently herewith


(replacement pages 95-98; attached hereto as Attachment A) was previously submitted in the parent '743 application. In accordance with 37 C.F.R. 1.821(e), please use the latest computer readable form of the Sequence Listing filed in the '743 parent application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make any necessary changes to the paper and computer readable form of the Sequence Listing to update the application number and filing date prior to incorporating the Sequence Listing into the instant application.

The information contained in the computer readable form of the Sequence Listing is identical to that of the paper copy and does not introduce new matter into the instant application.

No fees beyond those being submitted herewith are believed to be due in connection with the Response and Amendment. However, the Commissioner is authorized to charge any additional fees, including extension fees, which may be required, or credit any overpayment to Deposit Account No. 50-2319 [Our Order No. 470438-94 (A-72076-5/AMP)]. Please direct any calls in connection with this application to the undersigned at (650) 494-8700.

Respectfully submitted,
DORSEY & WHITNEY LLP

Dated: November 24, 2004

BY: 
Ann M. Caviani Pease, Reg. No. 42,067

Customer Number: 32940

Dorsey & Whitney LLP
Intellectual Property Department
Four Embarcadero Center, Suite 3400
San Francisco, CA 94111-4187
Telephone: (650) 494-8700
Facsimile: (650) 494-8771

6/16

